| Chimeric antigen receptor T cells in hematologic malignancies BR Shank, B Do, A Sevin, SE Chen, SS Neelapu, SB Horowitz Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 37 (3 …, 2017 | 74 | 2017 |
| Multiple myeloma maintenance therapy: a review of the pharmacologic treatment BR Shank, VT Brown, RN Schwartz Journal of Oncology Pharmacy Practice 21 (1), 36-51, 2015 | 40 | 2015 |
| The value of pharmacy residency training for health systems: an annotated bibliography JT Swan, M Giouroukakis, BR Shank, DJ Crona, K Berger, E Wombwell Journal of pharmacy practice 27 (4), 399-411, 2014 | 19 | 2014 |
| Corrected calcium versus ionized calcium measurements for identifying hypercalcemia in patients with multiple myeloma MJ Buege, B Do, HC Lee, DM Weber, SB Horowitz, L Feng, Y Qing, ... Cancer treatment and research communications 21, 100159, 2019 | 18 | 2019 |
| Adverse prognostic factors for morbidity and mortality during peripheral blood stem cell mobilization in patients with light chain amyloidosis JC Yeh, BR Shank, DR Milton, MH Qazilbash Biology of Blood and Marrow Transplantation 24 (4), 815-819, 2018 | 18 | 2018 |
| Stability of tacrolimus injection diluted in 0.9% sodium chloride injection and stored in Excel bags AL Myers, Y Zhang, JD Kawedia, BR Shank, MA Deaver, MA Kramer American Journal of Health-System Pharmacy 73 (24), 2083-2088, 2016 | 11 | 2016 |
| Demystifying drug dosing in obese patients BR Shank, ZE David ASHP, 2016 | 11 | 2016 |
| Advances in oncology pharmacy practice BR Shank, RN Schwartz, C Fortner, RS Finley American Journal of Health-System Pharmacy 72 (23), 2098-2100, 2015 | 11 | 2015 |
| Effects of the leucovorin shortage: Pilot study investigating cost, efficacy, and toxicity comparison of low fixed-dose versus body surface area-adjusted leucovorin dosing in … BR Shank, AH Seung, K Kinsman, MJ Newman, RC Donehower, B Burton Journal of Oncology Pharmacy Practice 23 (3), 163-172, 2017 | 9 | 2017 |
| Transitions of care in patients with cancer BR Shank, PAA Nguyen, EC Pherson The American journal of managed care 23 (7 Spec No.), SP280-SP284, 2017 | 8 | 2017 |
| New and emerging pharmacotherapies for the management of multiple myeloma DC Moore, CJ Oxencis, BR Shank American Journal of Health-System Pharmacy 79 (14), 1137-1145, 2022 | 7 | 2022 |
| Stability of pergolide mesylate oral liquid at room temperature BR Shank, CM Ofner III International Journal of Pharmaceutical Compounding 13 (3), 254, 2009 | 5 | 2009 |
| Cyclophosphamide desensitization in patients with severe hypersensitivity reactions to bendamustine B Figgins, B Primeaux, BR Shank, SE Chen, DM Weber, H Lu Journal of Oncology Pharmacy Practice 26 (4), 982-985, 2020 | 3 | 2020 |
| Multitemperature stability and degradation characteristics of pergolide mesylate oral liquid BR Shank, CM Ofner III Journal of Pharmacy Practice 23 (6), 570-574, 2010 | 3 | 2010 |
| Hyperfractionated cyclophosphamide and dexamethasone alone or in combination with daratumumab and/or carfilzomib for the treatment of relapsed or refractory multiple myeloma: a … BR Shank, B Primeaux, EK Yeung, SB Horowitz, IY Lee, L Roccograndi, ... Clinical Lymphoma Myeloma and Leukemia 23 (4), 279-290, 2023 | 2 | 2023 |
| Letermovir use in patients with relapsed or refractory hematological malignancies J Sassine, F Khawaja, BR Shank, A Lovell, J Lee, A DiPippo, C Rausch, ... 2021 TCT| Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, 2021 | 2 | 2021 |
| Hyperfractionated cyclophosphamide-dexamethasone (HyperCy-Dex) with or without carfilzomib (Car) in patients (pts) with multiple myeloma (MM) EK Yeung, BR Primeaux, SB Horowitz, BR Shank, IY Lee, GP Kaufman, ... Blood 136, 19-20, 2020 | 1 | 2020 |
| Weighing in on antibiotic dosing for surgical site prophylaxis DE Zimmerman, BR Shank American Journal of Health-System Pharmacy 77 (6), 408-409, 2020 | 1 | 2020 |
| 930. Clinically Significant CMV Infections in Patients with Lymphoma or Multiple Myeloma J Sassine, F Khawaja, BR Shank, A Lovell, J Lee, A DiPippo, CR Rausch, ... Open Forum Infectious Diseases 8 (Supplement_1), S557-S558, 2021 | | 2021 |
| Daratumumab (Dara) and hyperfractionated cyclophosphamide (HyperCy)/dexamethasone (Dex) with and without carfilzomib (Car) for the treatment of relapsed/refractory multiple … BR Shank, B Primeaux, SB Horowitz, EK Yeung, IY Lee, GP Kaufman, ... Journal of Clinical Oncology 38 (15_suppl), e20528-e20528, 2020 | | 2020 |
